Search results for "Mabs" in Articles / App Notes
Article
Recap: Chromatography + filtration virtual summit 2024
Don’t worry – here are the highlights and session recordings from the event on optimizing purification and filtration for mAbs, antibody variants, recombinant proteins, and gene therapy.
See highli…
Article
Detailed agenda for Chromatography + filtration virtual summit
We will also discuss recent innovations, such as Cytiva™ Protein Select™ technology, MabSelect™ VH3 resin, and MabSelect VL resin.
Registration is free of charge - see you there!
Register for …
Article
Register to the Chromatography + Filtration Virtual Summit 2024
Explore the latest advancements in process development and scale-up
5-7 March, 2024 - 15:00 - 18:00 CET all 3 days
Join Cytiva Chromatography and filtration summit online to lear…
Article
HTPD 2023 conference is coming up. What will be discussed and what happened last time?
Both the evolution of mature HTPD platforms for mAbs as well as the development of new HTPD approaches for nanoparticles like cells, viral vectors et al, will be discussed.
Learn more about HTPD …
Article
Pushing the Barriers in Next-Gen Antibody Development
Continued development of new and next-generation antibodies is spurred by the increasing demand for more effective and custom-tailored biologic therapies. In particular, bispecific antibodi…
Article
eBook: Purification of Antibody Therapeutics - Approach for Diversified Pipeline
Over the years, development beyond traditional monoclonal antibodies (mAbs) has increased. Today, we see multispecific and bispecific antibodies, antibody fragments, and antibody drug conjugates in th…
Article
Protein L affinity resin is ready to move to manufacturing
The MabSelect™ VL protein L resin now offers improved alkaline stability compared to Capto™ L resin and a two-fold or more increase in dynamic binding capacity (DBC) in certain applications. After com…
Article
Chromatography innovations for the diverse antibody pipeline
To support development of new therapeutic possibilities, manufacturing and process development technologies must also evolve. For antibody variants, platform purification protocols for conve…
Article
Late stage failures of monoclonal antibodies
Despite the significant developments that have happened in clinical trial design and the considerable experience that the biopharma industry has gained in the past three decades, therapeutic…
Article
Enhancing Resins Addresses Purification Concerns
“This has especially been true for the success of mAbs. Now, we start to see a new landscape based on a variety of new modalities such as viral vectors, mRNA, pDNA, cell and gene therapy, and oligos,”…